Neurobehavioral abnormalities may correlate with increased seizure burden in children with Panayiotopoulos syndrome

Yoshiko Hirano1, Hirokazu Oguni, Makoto Funatsuka

  • 1Department of Pediatrics, Tokyo Women's Medical University, Tokyo, Japan.

Pediatric Neurology
|May 13, 2009
PubMed

Insights

Prognostic factors for Panayiotopoulos syndrome were studied in 79 children. Pre-existing neurobehavioral disorders are linked to more frequent, pharmacoresistant seizures, but remission occurs by age 12.

Area of Science:

  • Neurology
  • Pediatric Epilepsy

Background:

  • Panayiotopoulos syndrome is a common childhood epilepsy syndrome.
  • Understanding prognostic factors is crucial for patient management.

Purpose of the Study:

  • To identify prognostic factors associated with frequent seizure recurrences in Panayiotopoulos syndrome.
  • To investigate the role of neurobehavioral disorders in seizure frequency and treatment response.

Main Methods:

  • Retrospective analysis of medical records and electroencephalograms of 79 children with Panayiotopoulos syndrome.
  • Classification of patients into typical, borderline, and atypical groups based on seizure recurrence frequency.
  • Analysis of various clinical and demographic factors, including neurobehavioral disorders.

Main Results:

  • A significant association was found between pre-existing neurobehavioral disorders and a higher frequency of seizures (>10 times) in the atypical group.
  • Patients with Panayiotopoulos syndrome and mild neurobehavioral disorders exhibited pharmacoresistant seizures that recurred frequently.
  • All patients achieved seizure remission by 12 years of age.

Conclusions:

  • Pre-existing neurobehavioral disorders are a significant prognostic factor for frequent, pharmacoresistant seizures in Panayiotopoulos syndrome.
  • Despite potential for frequent recurrences, Panayiotopoulos syndrome generally has a favorable long-term prognosis with seizure remission by adolescence.
  • Surgical evaluation is typically not indicated for patients with Panayiotopoulos syndrome.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
Seizures l: Introduction01:20

Seizures l: Introduction

Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...